Vanda Pharmaceuticals Inc. (VNDA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Vanda Pharmaceuticals reported revenue of $216.1M, up 8.7% from $198.8M the year before. Net income was -$220.5M (a -102.0% net margin), or -$3.74 per diluted share. Gross margin was -70.0% and operating margin was -70.0%. Operating activities generated -$109.4M of cash, leaving -$110.4M of free cash flow. At fiscal year end, Vanda Pharmaceuticals held $488.9M in total assets against $161.8M in total liabilities, including $84.9M of cash and equivalents.
Open the full interactive Vanda Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Vanda Pharmaceuticals Key Stats
| Share Price | $4.30 |
|---|---|
| Market Cap | $259.0M |
| Revenue YoY Growth | +8.7% |
| 52-Week Range | $4.30 – $9.56 |
| Shares Outstanding | 60.2 million (basic, 2026 Q2) |
Vanda Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $248.2M | $268.7M | $254.4M | $192.6M | $198.8M | $216.1M |
| Cost of Goods Sold | $220.9M | $226.5M | $248.1M | $206.6M | $239.4M | $367.3M |
| Gross Profit | $27.2M | $42.2M | $6.3M | -$14.0M | -$40.7M | -$151.2M |
| Operating Income | $27.2M | $42.2M | $6.3M | -$14.0M | -$40.7M | -$151.2M |
| Pre-Tax Income | $31.7M | $42.4M | $11.3M | $6.3M | -$22.9M | -$138.6M |
| Income Tax | $8.3M | $9.2M | $5.0M | $3.8M | -$4.0M | $81.8M |
| Net Income | $23.3M | $33.2M | $6.3M | $2.5M | -$18.9M | -$220.5M |
| Diluted EPS | $0.42 | $0.58 | $0.11 | $0.04 | -$0.33 | -$3.74 |
Vanda Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $56.3M | $57.2M | $51.7M | $50.5M |
| Net Income | -$22.6M | -$141.2M | -$48.6M | -$62.5M |
| Diluted EPS | -$0.38 | -$2.40 | -$0.82 | -$1.04 |
Vanda Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.0M | $52.1M | $135.0M | $135.8M | $102.3M | $84.9M |
| Current Assets | $409.1M | $478.3M | $519.3M | $432.9M | $438.9M | $347.3M |
| Total Assets | $533.5M | $593.8M | $634.2M | $648.4M | $656.2M | $488.9M |
| Current Liabilities | $65.9M | $74.4M | $91.4M | $87.7M | $100.0M | $145.2M |
| Total Liabilities | $80.2M | $88.9M | $107.0M | $103.5M | $117.7M | $161.8M |
| Shareholders' Equity | $453.3M | $504.9M | $527.2M | $544.9M | $538.5M | $327.2M |
Vanda Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $51.8M | $64.2M | $32.0M | $12.8M | -$15.8M | -$109.4M |
| Cash From Investing | -$41.5M | -$76.7M | $49.9M | -$12.1M | -$17.4M | $94.9M |
| Cash From Financing | $5.6M | $3.5M | $734,000 | $0 | -$155,000 | -$2.9M |
| Free Cash Flow | $50.0M | $63.7M | $31.3M | $12.4M | -$16.2M | -$110.4M |
Figures from Vanda Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vanda Pharmaceuticals financials page for every line item.
Vanda Pharmaceuticals Company Profile
| Ticker | VNDA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Washington, District of Columbia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001347178 |
Frequently Asked Questions
What was Vanda Pharmaceuticals' revenue in fiscal 2025?
Vanda Pharmaceuticals (VNDA) reported revenue of $216.1M for fiscal 2025.
What is Vanda Pharmaceuticals' annual revenue history?
Vanda Pharmaceuticals' annual revenue by fiscal year: 2020: $248.2M; 2021: $268.7M; 2022: $254.4M; 2023: $192.6M; 2024: $198.8M; 2025: $216.1M.
What was Vanda Pharmaceuticals' net income in fiscal 2025?
Vanda Pharmaceuticals reported net income of -$220.5M for fiscal 2025.
What was Vanda Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Vanda Pharmaceuticals' diluted EPS was -$3.74 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vanda Pharmaceuticals generate in fiscal 2025?
Vanda Pharmaceuticals generated -$110.4M of free cash flow in fiscal 2025.
What was Vanda Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Vanda Pharmaceuticals reported revenue of $50.5M.
How many shares of Vanda Pharmaceuticals are outstanding?
Vanda Pharmaceuticals reported a weighted average of 60.2 million basic shares outstanding in 2026 Q2.
What is Vanda Pharmaceuticals' market cap?
Based on its latest closing price, Vanda Pharmaceuticals (VNDA) has a market capitalization of about $259.0M.
When does Vanda Pharmaceuticals' fiscal year end?
Vanda Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Vanda Pharmaceuticals headquartered?
Vanda Pharmaceuticals lists its business address in Washington, District of Columbia in its SEC filings.